PATENT CLAIM ANALYSIS

Application Number: 15957322
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-05
Patent Classification: ["514", "003100"]

Abstract:
A glucosamine peptide compound or a pharmaceutically acceptable salt thereof are useful for treating liver metabolic disorders, wherein the glucosamine peptide compound may have the structure of Glc-L-Pep, and wherein Glc represents glucosamine moiety, L represents a linker, Pep represents a peptide moiety consisting of two to six amino acid residues, Glc and L are bonded by an ether linkage, and L and Pep are bonded by an amide linkage. The liver metabolic disorders include nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, alcoholic fatty liver disease, alcoholic steatohepatitis, hepatic steatosis, liver fibrosis, cirrhosis or a combination thereof.

Claim (Index 5):
The method of  claim 1 , wherein one or more hydroxyl groups of the glucosamine moiety is amino-modified, thio-modified, glycoside-modified, glucosamine-modified or acylated.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 91.0
- Lexical Diversity: 1.89655
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15868252', '14782415', '15725843', '15272619', '15715702']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.780566608147438
- 35 USC 102 Novelty (BERT): 0.4977454851324928
- Combined Prediction Score: 0.7522844958459434
- Mean Citation Score: 212.387448
- Max Citation Score: 216.8423
- Similarity Product: 147.57477574098706

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test